Experienceof subcutaneous allergen-specific immunotherapy with «Phostal» in children.
- Authors: Shakhova N.V.1, Gordeev VV1, Tokarev VP2, Borisenko TY.2, Kharchenko SS2, Kurenkova EN2, Shakhova NV3, Gordeev VV3, Tokarev VP4, Borisenko TY4, Kharchenko SS4, Kurenkova EN4
-
Affiliations:
- ГБОУ ВПО «Алтайский государственный медицинский университет»
- МУЗ «Детская городская клиническая больница № 7»
- Altai State Medical University
- Сity clinical children's hospital № 7
- Issue: Vol 8, No 6 (2011)
- Pages: 28-32
- Section: Articles
- URL: https://journals.rcsi.science/raj/article/view/121166
- DOI: https://doi.org/10.36691/RJA786
- ID: 121166
Cite item
Open Access
Access granted
Subscription Access
Abstract
immunotherapy (scIT ) using F ostal at pollinosis children.
Methods. 31 patient (19 boys and 12 girls) at the age from 5 to 16 with pollinosis with sensibilization to tree pollen
(birch, alder, hazel) allergens were observed. A ll patients were divided into 2 groups. T he first group consisted
of 11 children, which were treated with F ostal. T he second group was a control group, consisted of 20 children,
no treatment was assigned to them. A ll patients from both groups got the basis pollinosis therapy. Efficiency of
the scIT using F ostal was estimated in terms of its influence on the childrens quality of life, clinical symptoms
and drug load.
Results. Good results demonstrated in terms of increased quality of life indexes were achieved after the initial
stage of the scIT using F ostal. C ompared to the control group, the amount of needed drugs was significantly
decreased, and the decrease in the severity of clinical symptoms of rhinitis (p=0,001) and conjunctivitis (p=0,002)
was observed.
During the scIT with the F ostal trees pollen some negligible local reactions were observed in all cases, in 7 of 11
patients marked local reactions appeared. O n the initial stage of the therapy no systemic allergic reaction was
observed.
Conclusion. On the basis of the results of the study, F ostal could be considered as a highly effective and safe
for treatment of pollinosis children. S cIT with the F ostal leads to the improvement of childrens quality of life,
decreasing of clinical symptoms severity as well as drug load.
About the authors
Natal'ya Viktorovna Shakhova
ГБОУ ВПО «Алтайский государственный медицинский университет»
Email: Natalia.shakhova@mail.ru
ГБОУ ВПО «Алтайский государственный медицинский университет»
V V Gordeev
ГБОУ ВПО «Алтайский государственный медицинский университет»ГБОУ ВПО «Алтайский государственный медицинский университет»
V P Tokarev
МУЗ «Детская городская клиническая больница № 7»МУЗ «Детская городская клиническая больница № 7»
T Yu Borisenko
МУЗ «Детская городская клиническая больница № 7»МУЗ «Детская городская клиническая больница № 7»
S S Kharchenko
МУЗ «Детская городская клиническая больница № 7»МУЗ «Детская городская клиническая больница № 7»
E N Kurenkova
МУЗ «Детская городская клиническая больница № 7»МУЗ «Детская городская клиническая больница № 7»
N V Shakhova
Altai State Medical UniversityAltai State Medical University
V V Gordeev
Altai State Medical UniversityAltai State Medical University
V P Tokarev
Сity clinical children's hospital № 7Сity clinical children's hospital № 7
T Y Borisenko
Сity clinical children's hospital № 7Сity clinical children's hospital № 7
S S Kharchenko
Сity clinical children's hospital № 7Сity clinical children's hospital № 7
E N Kurenkova
Сity clinical children's hospital № 7Сity clinical children's hospital № 7
References
- Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. М., «Фармарус Принт Медиа». 2010,223 с.
- Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy. 1999, v. 54, p. 1022-1041.
- Mailing H.J. Allergen immunotherapy efficacy in rhinitis and asthma. Allergy Clin. Immunol. Int. J. World Allergy Org. 2004, v. 16 (3), p. 92-95.
- Курбачева О.М. Аллерген-специфическая иммунотерапия. Рос. Аллергол. Журн. 2004, № 2, с. 32-54.
- Moller С., Dreborg S., Ferdousi Н.А. et al. Pollen immuno-
- therapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-stady). J. Allergy. Clin. Immunol. 2002, v. 109, p. 251-256.
- Kumar P., Kamboj S., Rao P. et al. The cost of care and quality of life in patients with allergic rhinitis on allergen immunotherapy J. Allergy. Clin. Immun. Intern. 1997, v. 9 (5), p. 133-135.
- Yilmaz M., Bingol G., Altindas D. et al. Effect of SIT on quality of life. Allergy. 2000, v. 55, p. 302-309.
- Standards for practical allergen-specific immunotherapy. Allergy. 2006, v. 61, Suppl. 82, p. 1-20.
- Botey J., Cadahia A., Cobo R. et al. Tolerancia de la immunoterapia especifica con extractos alergenicos adsorbidos sobre fostato de calico. Rev. Esp. Alergolo Immunol. Clin. 1997, v. 12, p. 45-50.
- Donat N., Thibaudon M., Peltre G., David B. Desensibilisation par des extraits de pollen adsorbes sur phosphate de calcium pedant 4 annes consecutives: etud des serum par immunoempreintes, RAST et PRIST.
- Fadel R., Andre C., Bellanger M. et al. Tolerans, compliance et efficacite de immunotherapia specifique par des extraits allergeniques aqueus ou adsorbes sur phosphate de calcium. Etude retrospective. Rev. Fr. Allergol. 1998, v. 38, p. 41-49.
- Курбачева О.М., Павлова К.С., Ильина Н.И. и соавт. Эффективность проведения аллерген-специфической иммунотерапии препаратом «Фосталь» у больных поллинозом. Рос. Аллергол. Журн. 2009, № 3, с. 27-31.
- Varni J.W., Seid M., Kurtin PS. Pediatric health-related quality of life measurement technology: A guide for health care decision makers. J. Clin. Outcomes Manag. 1999, v. 6, p. 33-40
Supplementary files
